Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
88249-1-PBS targets Cleaved GSDME (Asp270), C-terminal in WB, FC (Intra), Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen |
Peptide 相同性解析による交差性が予測される生物種 |
| Full Name | deafness, autosomal dominant 5 |
| Calculated molecular weight | 496 aa, 55 kDa |
| Observed molecular weight | 25 kDa |
| GenBank accession number | BC019689 |
| Gene Symbol | DFNA5 |
| Gene ID (NCBI) | 1687 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | O60443 |
| Storage Buffer | PBS only{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
GSDME, also known as DFNA5 (deafness, autosomal dominant 5), is a member of the gasdermin family of pore-forming proteins. In its full-length form, GSDME is autoinhibited. Upon apoptotic stimulation, active caspase-3 specifically cleaves GSDME at a conserved aspartate residue, Asp270 (D270). This cleavage of Gasdermin E separates the N‑terminal pore‑forming domain from the C‑terminal repressor domain. The released N‑terminal fragment then inserts into the plasma membrane, forms large pores, and induces a lytic, inflammatory form of cell death known as pyroptosis. Therefore, Asp270 cleavage is a critical molecular switch that converts caspase‑3‑mediated apoptosis into pyroptosis, linking GSDME/DFNA5 to cancer therapy, chemotherapy‑induced toxicity, and hearing loss pathology.